568 results for "krytan tek side effects"

Search for:

Date Range to

568 Results on GlaucomaToday.com

October 2015October 2015

The Literature By Benjamin Abramowitz, MD, and Nisha Chadha, MD

Cochlin as a Glaucoma Molecular Biomarker Research may allow clinicians to initiate treatment before the disease damages patients’ optic nerves and visual fields.
By Sanjoy K. Bhattacharya, M Tech, PhD, and Richard K. Lee, MD, PhD

Risk Factors in Glaucomatous Progression IOP remains the only modifiable risk factor, but fixed, historic risk factors may help clinicians set the initial target pressure and the length of follow-up intervals.
By Ta Chen Peter Chang, MD, and Elizabeth A. Hodapp, MD

Assessing Imaging Progression By analyzing the thickness of the retinal nerve fiber layer, optical coherence tomography detects and quantifies glaucomatous progression.
By Murray Fingeret, OD

Setting Target Pressures Aim for a range instead of a number to more fully account for each patient’s needs.
By Inder Paul Singh, MD

Monitoring Patients With Advanced Glaucoma Because they are at high risk of disease progression and blindness, these individuals require special attention.
By Darrell WuDunn, MD, PhD

Designing a Clinical Trial for Glaucoma Treatments Which endpoints should be used?
By Michael Waisbourd, MD; Lisa A. Hark, PhD, RD; and L. Jay Katz, MD

Determining Factors in Intensifying Glaucoma Management Take the whole patient into account.
By Kelly W. Muir, MD, MHSc

Adding Insult to Injury The contribution of systemic medication to dry eye disease.
By Sejal R. Amin, MD, and Christopher T. Hood, MD

Q&A With Glaukos CEO Thomas Burns The process of validating a new category in glaucoma and transitioning from a startup to a public company.MD
By Stephen Daily, Executive Editor, News, BMC

August 2015August 2015

Pupillary Expansion A valuable ally for cataract extraction in glaucoma patients.
By Albert S. Khouri, MD

Integrating Research Into a Busy Clinical Practice A discussion of the potential benefits and tips for getting started.
By George R. Reiss, MD

Generic Versus Branded Glaucoma Drugs Generic medications offer therapeutic benefits for some patients.
By Marcos Reyes, MD, and Lauren Wiggins, MD

Glaucoma Drugs in the Pipeline Physicians share which coming therapies they are most eager to use in their practices.
By Malik Y. Kahook, MD; Paul L. Kaufman, MD; Robert J. Noecker, MD, MBA; and Nathan M. Radcliffe, MD

June 2015June 2015

The Literature By Kevin Kaplowitz, MD, and Osamah Saeedi, MD

Therapeutically Targeting Disease in Glaucoma New findings of glaucomatous changes in Schlemm canal cells point to the possibility of directing treatment to restore the function of diseased outflow tissue.
By Mark Johnson, PhD, and W. Daniel Stamer, PhD

Cataract Surgery in High-Risk Glaucoma Patients Do the risks outweigh the benefits?
By Aaron M. Marble, BS; Bradley P. Roth, MS; and Barbara A. Smit, MD, PhD

Management of Hypotony After Device Implantation By Jeffrey R. SooHoo, MD; Leonard K. Seibold, MD; and Malik Y. Kahook, MD

Stem Cells in Glaucoma Therapy The next several years should bring advances.
By David I. Green, BS, and Yvonne Ou, MD

New Trends in Medical Therapy for Glaucoma Drugs and delivery systems in development offer the hope of better options for individualized treatment.
By Sunita Radhakrishnan, MD

Optimizing Refractive Outcomes After Trabeculectomy and Aqueous Shunt Surgery Patients’ visual outcomes are important but often overlooked.
By Cynthia Mattox, MD

Impact of MIGS on Glaucoma Decision Making Physicians must strike a balance in the face of complexity.
By Andrew G. Iwach, MD

Point/Counterpoint: Should Patients Share the Cost of MIGS Procedures? By John Berdahl, MD, and Quang H. Nguyen, MD

The Effects of Economic Profiling on Ophthalmic Practice How payers are guiding patients away from specialists’ offices.
By Ruth D. Williams, MD

Optimizing Angle Surgery With ACT By Shakeel Shareef, MD

April 2015April 2015

The Literature By Helen Kornmann, MD, PhD, and Joseph F. Panarelli, MD

Highlights of the AGS Annual Meeting The latest research findings from the 25th annual meeting of the American Glaucoma Society, held February 26 to March 1, 2015, in Coronado, California.
By Geoffrey T. Emerick, MD

A Resident Reflects on Clinical Glaucoma Rotation By Anton Kolomeyer, MD, PhD

Evaluating the Anterior Chamber Angle A combination of techniques can yield a clear picture.
By Robert M. Feldman, MD

When Should I Perform Lens Extraction Alone for the Primary Angle-Closure Suspect? By Nicholas P. Bell, MD and Garry P. Condon, MD

LPI, Iridoplasty, or ECP for Chronic Angle-Closure Glaucoma? Laser treatment remains a mainstay of management.
By Shan Lin, MD

Lens Extraction in Angle-Closure Glaucoma Cataract surgery is an effective treatment that saves patients from the complications of trabeculectomy.
By Reay H. Brown, MD

Goniosynechialysis and Chronic Angle-Closure Glaucoma A safer option for patients with a cataract and uncontrolled glaucoma.
By Marlene R. Moster, MD, and Wanda D. Hu, MD

Filtration Surgery and Primary Angle-Closure Glaucoma Choose a surgical approach based on the contributing mechanism and stage of the disease.
By Sarwat Salim, MD

Industry News and Innovations

Why Are There Not More Pharmacotherapies for Glaucoma? There is plenty of interest but relatively few drugs in advanced-stage development.
By Gary D. Novack, PhD

February 2015February 2015

The Business of Glaucoma By Steven D. Vold, MD

Outflow Resistance An analysis of early and recent research.
By Murray Johnstone, MD

Steroid Therapy and IOP Along with the benefits of intravitreal injections and sustained-release implants comes the risk of steroid-induced ocular hypertension.
By Bradley P. Roth, MS, And Barbara Smit, MD, PhD

Gonioscopy-Assisted Transluminal Trabeculotomy: Blending Tradition With Innovation The ab interno approach may prove to be the safest and most effective for glaucoma surgery.
By Aaron Barrett, MLS(ASCP), And Craig Chaya, MD

123456789101112131415 | Next >